Sign in to unlock AI Chat and more features

High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes

American Society of Clinical Oncology Educational Book

Steven G. DuBois, Margaret E. Macy,, Tara O. Henderson

Citations:

77

References:

92

Abstract

Approximately half of the patients diagnosed with neuroblastoma are classified as having high-risk disease. This group continues to have inadequate cure rates despite multiagent chemotherapy, surgery, high-dose chemotherapy with autologous stem cell rescue, and immunotherapy directed against GD2. We review current efforts to try to improve outcomes in patients with newly diagnosed disease by integ...

Keywords

Medicine

Neuroblastoma

Disease

Refractory (planetary science)

Intensive care medicine

Chemotherapy

Oncology

Immunotherapy

Internal medicine

Surgery

Cancer

Genetics

Physics

Astrobiology

Biology

Cell culture

Sustainable Development Goals (SDG)

Good health and well-being

2022

Review

Open Access

Institution

Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215;,

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA,

Dana-Farber Cancer Institute,

Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO,

Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL

Publisher

American Society of Clinical Oncology

2-Y Citation Average

9.64

DOI

https://doi.org/10.1200/edbk_349783

Language

Country

High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes

High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes

American Society of Clinical Oncology Educational Book

Steven G. DuBois, Margaret E. Macy,, Tara O. Henderson

Citations:

77

References:

92

Abstract

Approximately half of the patients diagnosed with neuroblastoma are classified as having high-risk disease. This group continues to have inadequate cure rates despite multiagent chemotherapy, surgery, high-dose chemotherapy with autologous stem cell rescue, and immunotherapy directed against GD2. We review current efforts to try to improve outcomes in patients with newly diagnosed disease by integ...

Keywords

Medicine

Neuroblastoma

Disease

Refractory (planetary science)

Intensive care medicine

Chemotherapy

Oncology

Immunotherapy

Internal medicine

Surgery

Cancer

Genetics

Physics

Astrobiology

Biology

Cell culture

Sustainable Development Goals (SDG)

Good health and well-being

2022

Review

Open Access

Institution

Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215;,

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA,

Dana-Farber Cancer Institute,

Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO,

Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL

Publisher

American Society of Clinical Oncology

2-Y Citation Average

9.64

DOI

https://doi.org/10.1200/edbk_349783

Language

Country